Hamilton Thorne (TSX:HTL) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

HTL Overzicht aandelen

Hamilton Thorne Ltd. ontwikkelt, produceert en verkoopt precisie-instrumenten, laboratoriumapparatuur, verbruiksartikelen, software en diensten voor de markten van geassisteerde voortplantingstechnologieën (ART), onderzoek en celbiologie.

Over het bedrijf

HTL fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	4/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Verhandeld tegen 50.9% onder onze schatting van de reële waarde

De winst zal naar verwachting met 145.94% per jaar groeien

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar verwaterd

Volatiele aandelenkoers in de afgelopen 3 maanden

Hamilton Thorne Ltd. Concurrenten

Opsens

TSX:OPS

CA$335.8m

Profound Medical

TSX:PRN

CA$262.9m

Theralase Technologies

TSXV:TLT

CA$44.9m

Nanalysis Scientific

TSXV:NSCI

CA$45.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Hamilton Thorne
Historische aandelenkoersen
Huidige aandelenkoers	CA$2.18
52 Week Hoogtepunt	CA$2.20
52 Week Laag	CA$1.05
Bèta	0.42
11 maand verandering	1.40%
3 maanden verandering	56.83%
1 Jaar Verandering	74.40%
33 jaar verandering	32.12%
5 jaar verandering	118.00%
Verandering sinds IPO	473.68%

Recent nieuws en updates

A Piece Of The Puzzle Missing From Hamilton Thorne Ltd.'s (TSE:HTL) 47% Share Price Climb

Jul 29

Recent updates

A Piece Of The Puzzle Missing From Hamilton Thorne Ltd.'s (TSE:HTL) 47% Share Price Climb

Jul 29

These 4 Measures Indicate That Hamilton Thorne (CVE:HTL) Is Using Debt Reasonably Well

Aug 15

Announcing: Hamilton Thorne (CVE:HTL) Stock Soared An Exciting 590% In The Last Five Years

Jan 19

Are Insiders Selling Hamilton Thorne Ltd. (CVE:HTL) Stock?

Jan 06

What Did Hamilton Thorne's (CVE:HTL) CEO Take Home Last Year?

Dec 24

We Think Hamilton Thorne (CVE:HTL) Can Stay On Top Of Its Debt

Dec 12

Is It Time To Consider Buying Hamilton Thorne Ltd. (CVE:HTL)?

Nov 30

A Look At The Fair Value Of Hamilton Thorne Ltd. (CVE:HTL)

Nov 17

Rendement voor aandeelhouders

	HTL	CA Medical Equipment	CA Markt
7D	0.5%	1.5%	0.4%
1Y	74.4%	-7.5%	24.6%

Rendement versus industrie: HTL overtrof de Canadian Medical Equipment industrie, die het afgelopen jaar een rendement -7.5 % opleverde.

Rendement versus markt: HTL overtrof de Canadian markt, die het afgelopen jaar een rendement opleverde van 24.6 %.

Prijsvolatiliteit

Is HTL's price volatile compared to industry and market?
HTL volatility
HTL Average Weekly Movement	13.9%
Medical Equipment Industry Average Movement	10.4%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.1%
10% least volatile stocks in CA Market	3.0%

Stabiele aandelenkoers: De aandelenkoers van HTL is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van HTL is het afgelopen jaar gestegen van 9% naar 14%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	n/a	Kate Torchilin	www.hamiltonthorne.ltd

Hamilton Thorne Ltd. ontwikkelt, produceert en verkoopt precisie-instrumenten, laboratoriumapparatuur, verbruiksartikelen, software en diensten voor de markten voor geassisteerde voortplantingstechnologieën (ART), onderzoek en celbiologie. Het bedrijf biedt precisielasersystemen en beeldvormingssystemen voor de biologiemarkt. Het bedrijf levert ook diensten op het gebied van testlaboratoria en endotoxinetests, evenals sperma-analyses, waaronder de motiliteitsindex van sperma en de penetratie van sperma; levering van verse en gecryopreserveerde muizenembryo's en diensten op het gebied van technologietraining en bekwaamheidstests.

Hamilton Thorne Ltd. Samenvatting

Hoe verhouden de winst en inkomsten van Hamilton Thorne zich tot de beurswaarde?
HTL fundamentele statistieken
Marktkapitalisatie	CA$334.74m
Inkomsten(TTM)	-CA$2.29m
Inkomsten(TTM)	CA$98.22m

3.4x

P/S-verhouding

-146.2x

Koers/Winstverhouding

Is HTL overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
HTL resultatenrekening (TTM)
Inkomsten	US$72.57m
Kosten van inkomsten	US$35.80m
Brutowinst	US$36.78m
Overige uitgaven	US$38.47m
Inkomsten	-US$1.70m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.011
Brutomarge	50.68%
Nettowinstmarge	-2.34%
Schuld/Eigen Vermogen Verhouding	32.0%

Hoe presteerde HTL op de lange termijn?

Bekijk historische prestaties en vergelijking

HTL Overzicht aandelen

Beloningen

Risicoanalyse

Hamilton Thorne Ltd. Concurrenten

TSX:OPS

CA$335.8m

TSX:PRN

CA$262.9m

TSXV:TLT

CA$44.9m

TSXV:NSCI

CA$45.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Second quarter 2024 earnings released: US$0.003 loss per share (vs US$0.003 loss in 2Q 2023)

Hamilton Thorne Ltd. to Report Q2, 2024 Results on Aug 14, 2024

A Piece Of The Puzzle Missing From Hamilton Thorne Ltd.'s (TSE:HTL) 47% Share Price Climb

New minor risk - Share price stability

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Second quarter 2024 earnings released: US$0.003 loss per share (vs US$0.003 loss in 2Q 2023)

Hamilton Thorne Ltd. to Report Q2, 2024 Results on Aug 14, 2024

A Piece Of The Puzzle Missing From Hamilton Thorne Ltd.'s (TSE:HTL) 47% Share Price Climb

New minor risk - Share price stability

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hamilton Thorne Ltd. to Report Q1, 2024 Results on May 14, 2024

Hamilton Thorne Ltd., Annual General Meeting, Jun 11, 2024

Full year 2023 earnings released: US$0.004 loss per share (vs US$0.013 profit in FY 2022)

Hamilton Thorne Ltd. Provides Earnings Guidance for the First Quarter 2024 and Full Twelve Months of 2024

Hamilton Thorne Ltd. to Report Q4, 2023 Results on Mar 27, 2024

Hamilton Thorne Ltd. Announces CEO Changes, Effective January 15, 2024

New major risk - Revenue and earnings growth

Hamilton Thorne Ltd. to Report Q3, 2023 Results on Nov 13, 2023

Hamilton Thorne Ltd. (TSX:HTL) agreed to acquire Gynetics Medical Products N.V. for an enterprise value of €18.3 million.

Consensus EPS estimates increase by 80%

New minor risk - Shareholder dilution

Hamilton Thorne Ltd.(TSXV:HTL) dropped from S&P/TSX Venture Composite Index

Consensus EPS estimates fall by 80%

Second quarter 2023 earnings released: US$0.003 loss per share (vs US$0.002 profit in 2Q 2022)

These 4 Measures Indicate That Hamilton Thorne (CVE:HTL) Is Using Debt Reasonably Well

Hamilton Thorne Ltd. to Report Q2, 2023 Results on Aug 17, 2023

Consensus EPS estimates fall by 50%

First quarter 2023 earnings released: EPS: US$0.001 (vs US$0.004 in 1Q 2022)

Hamilton Thorne Ltd. to Report Q1, 2023 Results on May 15, 2023

Chair, President & CEO exercised options to buy CA$102k worth of stock.

Chair, President & CEO recently sold CA$101k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Now 20% undervalued

Consensus EPS estimates increase by 17%

Now 20% undervalued after recent price drop

Hamilton Thorne Ltd. Announces Passing of Diarmaid Douglas-Hamilton, Cofounder and Chief Technology Officer

Now 21% undervalued after recent price drop

Hamilton Thorne Ltd. (TSXV:HTL) agreed to acquire Microptic, S.L.

Consensus EPS estimates fall by 33%

Hamilton Thorne Ltd. Provides Sales Guidance for the Year 2022

Third quarter 2022 earnings released: EPS: US$0.001 (vs US$0.002 in 3Q 2021)

High number of new directors

Hamilton Thorne Ltd. to Report Nine Months, 2022 Results on Nov 22, 2022

Consensus EPS estimates fall by 23%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Hamilton Thorne Ltd. to Report Q2, 2022 Results on Aug 23, 2022

Hamilton Thorne Ltd. Announces CFO Changes

Chair, President exercised options to buy CA$86k worth of stock.

Chair, President exercised options to buy CA$886k worth of stock.

Consensus EPS estimates fall by 20%

At CA$1.40, Is Hamilton Thorne Ltd. (CVE:HTL) Worth Looking At Closely?

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Hamilton Thorne Ltd. to Report Q1, 2022 Results on May 19, 2022

Investor sentiment deteriorated over the past week

High number of new directors

Hamilton Thorne Ltd., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings: EPS exceeds analyst expectations

Chair, President exercised options to buy CA$293k worth of stock.

Hamilton Thorne Ltd. to Report Q4, 2021 Results on Apr 07, 2022

Is Hamilton Thorne (CVE:HTL) Using Too Much Debt?

High number of new directors

President recently bought CA$75k worth of stock

President recently sold CA$635k worth of stock

Third quarter 2021 earnings: EPS and revenues miss analyst expectations